Institut d'Investigacions Biomèdiques August Pi i Sunyer-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2022

  1. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    Blood, Vol. 140, Núm. 1, pp. 38-44

  2. Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis

    Journal of Proteomics, Vol. 251

2020

  1. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

  2. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

2017

  1. A multicentric study to evaluate the use of relative retention times in targeted proteomics

    Journal of Proteomics, Vol. 152, pp. 138-149

2016

  1. First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases

    Science Translational Medicine, Vol. 8, Núm. 370

2015

  1. Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML

    American Journal of Clinical Pathology, Vol. 144, Núm. 3, pp. 484-492

  2. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2013

  1. A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300

    Gut, Vol. 62, Núm. 10, pp. 1440-1445

  2. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

2002

  1. Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

    British Journal of Haematology, Vol. 118, Núm. 1, pp. 239-242